Karolina Vilval
Consigliere Generale presso SEDANA MEDICAL AB
Posizioni attive di Karolina Vilval
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| SEDANA MEDICAL AB | Consigliere Generale | 01/08/2022 | - |
| Oncopeptides Incentive AB | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Karolina Vilval
Precedenti posizioni note di Karolina Vilval
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ONCOPEPTIDES AB | Consigliere Generale | 02/03/2020 | 01/08/2022 |
| Gilead Sciences Sweden AB | Consigliere Generale | - | - |
| SWEDISH ORPHAN BIOVITRUM AB | Consigliere Generale | - | - |
Biovitrum AB
 Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Consigliere Generale | - | - |
Formazione di Karolina Vilval
| University of Stockholm | Graduate Degree |
Statistiche
Distribuzione geografica
| Svezia | 8 |
Posizioni
| General Counsel | 5 |
| Graduate Degree | 1 |
| Director/Board Member | 1 |
Settori
| Health Technology | 4 |
| Commercial Services | 2 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| ONCOPEPTIDES AB | Health Technology |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| SEDANA MEDICAL AB | Health Technology |
| Aziende private | 3 |
|---|---|
Biovitrum AB
Biovitrum AB Miscellaneous Commercial ServicesCommercial Services Biovitrum AB develops and sells specialist pharmaceuticals that improve people's lives. The company's business goal is to create a pharmaceutical company with long-term profitability through the international launch and sale of in-house developed products. Research expertise and capabilities are focused on development and production of biotechnology therapeutics within the prioritized areas of hemophilia, inflammation/autoimmune diseases, cancer supportive care and malabsorption. The company was founded in January 2001 and is headquartered in Stockholm, Sweden. | Commercial Services |
| Gilead Sciences Sweden AB | |
| Oncopeptides Incentive AB |
- Borsa valori
- Insiders
- Karolina Vilval
- Esperienza
